CNS THERAPEUTICS XCHANGE
EAST COAST 2023
Boston
May 24, 2023
May 24, 2023
Welcome to hubXchange’s CNS Therapeutics Xchange East Coast 2023, bringing together executives from pharma and biotech to address and find solutions to the key issues faced in developing CNS therapies.
Discussion topics will cover Novel Targets, Preclinical, Clinical Studies and Drug Delivery.
Take advantage of this unique highly interactive meeting format designed for maximum engagement, collaboration and networking with your peers.
Please note this is an In-Person meeting.
VENUE DETAILS: Hilton Boston Woburn Hotel, 2 Forbes Road, Woburn MA 01801
SNAPSHOTS OF DISCUSSION TOPICS
- Novel therapies for complex neurological disorders: discovery of effective treatments
- Opportunities from emerging therapeutic modalities: Target selection in an evolving druggability landscape
- Methods to increase the success rates of drugs entering clinical phases
- Novel strategies for reverse translation of temporal biomarkers for CNS drug development
- Relevant in vitro mechanistic profiling to guide SAR and downstream in vivo studies
- Utilizing clinical biomarkers to enhance drug development in neurodegenerative diseases
- Are circulating neurodegeneration biomarkers ready for prime time?
- Fluid and digital biomarkers in neurodegenerative disorders
- Transcytosis-mediated brain delivery for proteins, antibodies, oligonucleotides, and small molecules
- Non-invasive methods to increase brain drug uptake
Full Xchange Agenda
Click on each track for detailed agenda
Novel Targets
09:05 – 10:05
Novel therapies for complex neurological disorders: discovery of effective treatments
Vice President – Global Medical Affairs, Praxis Precision Medicines
Networking Lunch
1-2-1 Meetings / Networking Break
1-2-1 Meetings / Networking Break
15:35 – 16:35
Opportunities from emerging therapeutic modalities: Target selection in an evolving druggability landscape
R&D Director of Advanced Analytical Sciences, Noveome Biotherapeutics, Inc.
Preclinical
09:05 – 10:05
Methods to increase the success rates of drugs entering clinical phases
Vice President, Head of Biology, Cerevel Therapeutics
Phil did his PhD and a brief post doc in signal transduction mechanisms in CNS at the University of Nottingham in the UK. In 1994 he joined the Duman/Nestler lab at Yale investigating the molecular regulation of CRF receptors and, exploring the role the receptor plays in withdrawal from drugs of abuse. He joined Pfizer in 1997 as a lab head where he took on increasingly senior roles leading several programs incuding CB1 agonists/antagonists, psychosis disease space. In 2004 he joined the CNS management team and subsequently headed several programs in neuroscience, neurology and external collaborations which led to therapeutic area operational oversight as well as Kendall Sqauare MA site responsibilities. In 2018 Pfizer announced that it was exiting Neuroscience. Phil subsequently joined Cerevel Therapeutics as Head of Biology in October of 2018.
Novel strategies for reverse translation of temporal biomarkers for CNS drug development
Global Head, Neuroscience Search & Evaluation, AbbVie
- Not having the right in vitro assay, or relying heavily on a single work-horse assay can lead to:
- Low quality hit rate from HTS (low confirmation)
- Not tractable SAR
- Unable to improve SAR
- SAR moving in the wrong direction
- Selecting the wrong molecule into in vivo
- Low quality hit rate from HTS (low confirmation)
- Should we invest more resources for deeper mechanistic profiling (kinetics, signaling pathways, etc.)? Or should we move molecules into in vivo models ASAP?
Director, Head of In Vitro Pharmacology, Cerevel
Sokhom Pin is currently the head of in vitro pharmacology at Cerevel Therapeutics, where his team is engaged in exploring novel targets, assay development/screening, as well as mechanistic profiling of late-stage molecules. Prior to Cerevel, he built and lead a similar team at Alkermes, Inc.. Sokhom has over 20 years of drug discovery experience at large and mid-sized pharma’s, including DuPont, BMS, and Novartis. He has a strong passion is GPCR pharmacology and neuroscience drug discovery. He received his Ph.D. in Pharmaceutical Sciences (Pharmacology/Toxicology) from the University of Connecticut and his M.S. from the Johns Hopkins University.
Clinical Studies
Registration
Utilizing clinical biomarkers to enhance drug development in neurodegenerative diseases
Executive Director, Translational Medicine, Eisai US
Morning Refreshments
15:35 – 16:35
Are circulating neurodegeneration biomarkers ready for prime time?
- Inflammation: what is the state of the art of inflammation-based biomarkers in AD? We can measure in animal models but how well are we able to precisely monitor brain markers of brain inflammation in humans?
- Synapse function: what are the most reliable markers of synapse architecture, function and integrity? Are these being deployed in human trials?
- Everything else: what have we learned from targeting Abeta after all these decades? We cured mice with AD but not people so clearly there is a disconnected – lets discuss. Are there other yet-to-be-studied markers or mechanisms associated with Abeta signaling, accumulation or plaque formation?
Chief Executive Officer, Kures
Chad Beyer is CEO of Kures and formerly CEO and Head of R&D at Promentis Pharmaceuticals. Dr. Beyer has 25 years of experience in biotech fundraising and the development of novel, disease-modifying medications. Prior to Promentis, Dr. Beyer was the SVP of R&D at Ariel Pharmaceuticals and Head of Neurochemistry at Wyeth Pharmaceuticals. Dr. Beyer contributed to the commercialization of two blockbuster medications and holds a Ph.D. in neuropharmacology from LSU Medical Center and an MBA from the Rutgers Business School. He has served on the Board of Directors of several companies, authored more than 70 manuscripts, and is the Entrepreneur in Residence at Lafayette College.
16:45 – 17:45
Fluid and digital biomarkers in neurodegenerative disorders
Associate Director, Medical Affairs, Click Therapeutics
Drug Delivery
Transcytosis-mediated brain delivery for proteins, antibodies, oligonucleotides, and small molecules
Founder, Chairman & Chief Executive Officer, Lauren Sciences LLC
1-2-1 Meetings / Networking Break
1-2-1 Meetings / Networking Break
Non-invasive methods to increase brain drug uptake
Senior Director, External Neuroscience Innovation Neuroscience Drug Discovery Unit, Takeda